This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi, Amgen see competing claims over PCSK9 patent both dismissed by UPC

( May 13, 2025, 08:48 GMT | Official Statement) -- MLex Summary: Both French drugmaker Sanofi's infringement action and US rival Amgen 's counterclaim for revocation regarding European patent 3,536,712 B1 have been dismissed by the Unified Patent Court’s Düsseldorf Local Division. The court found that Amgen’s marketing of the PCSK9 inhibitor, Repatha, didn't demonstrably achieve the claimed therapeutic effect of lowering elevated lipoprotein levels. Insufficient evidence was provided to show that Repatha was promoted for this specific use, the court said. Consequently, both claims were dismissed and each party was ordered to bear its own costs.  The decision is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections